Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2017 · 10-Q
Revenue$57.58M$57.58M+30.3% vs Q1 2016 Net Income$10.30M$10.30M+113.4% vs Q1 2016 EPS Diluted$0.19$0.19+137.5% vs Q1 2016 Operating Income$16,788,000+160.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$13,058,000N/M Margins · derivedOperating margin29.2%+14.6 pt vs Q1 2016
Net margin17.9%+7.0 pt vs Q1 2016
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end